Boston Scientific Corp., Natick Mass., and Guidant Corp., Indianapolis, said they have settled all litigation regarding patent infringement on coronary stents, coronary stent delivery systems and dilatation catheters. The companies did not disclose details of the settlement but said it dismisses all pending disputes. They also have agreed to cross-license patents for certain unspecified technologies. Officials at both companies said they were pleased with the agreement. The settlement arrives as Boston Scientific awaits Food and Drug Administration marketing approval of its Taxus drug-eluting stent. Taxus would be only the second such stent to enter the U.S. market since the FDA approved Johnson & Johnson's Cypher last April. Guidant's entry was delayed by the litigation with Boston Scientific. -- by Cinda Becker
Boston, Guidant settle coronary stent disputes
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.